Elsevier Inspires Physicians to “Be The Best Doctor You Can Be” with the 25th Edition of Goldman-Cecil Medicine at ACP 2015
most influential internal medicine resource is the fastest and best place to
find authoritative, state-of-the-art clinical answers
The world’s most influential internal medicine resource is the fastest and best place to find authoritative, state-of-the-art clinical answers
Elsevier, a world-leading
provider of scientific, technical and medical information products and
services, today announced the publication of the 25th edition of Goldman-Cecil
Medicine. The new edition is
launching with a ground-breaking update program that provides readers access to
the most current content available in the field with the included eBook. The 25th
edition will be showcased at the American College of Physicians (ACP) 2015
Internal Medicine Conference held in Boston from April 28 – May 2, 2015. At
10:30 am, Friday, May 1, Dr. Lee Goldman will be at the Elsevier booth (#1209)
for a meet and greet.
“Goldman-Cecil Medicine has been compiled to provide an ideal learning tool for residents, physicians, and students as well as a valuable go-to resource for experienced healthcare professionals,” Goldman said. “It includes a powerful Expert Consult eBook platform that creates a ‘living text,’ providing continuous updates that I select and are integrated into each chapter. This ensures that the content is as current as the day the book was published.”
Since its first edition in 1927, Goldman-Cecil Medicine has been the world’s most influential internal medicine resource. The new edition includes current information on the latest research, guidelines and drug standards. Those who purchase the print edition will also receive the Expert Consult eBook version that includes an interactive Q&A section to assist medical professionals in preparing for board and maintenance of certification exams, and supplementary tools such as videos, references and illustrations.
Other key features of the 25th edition include:
- Practical, bulleted text with easy-to-use features including flow charts and treatment boxes;
- New chapters on global health, cancer biology and genetics, and the human microbiome in health and disease;
- Today's most current evidence-based medicine guidelines to assist in definitive diagnosis and creation of the best treatment plans possible;
- Focused coverage of the latest developments in biology, including the specifics of current diagnosis, therapy, and medication doses;
- The ability to view or download content via mobile devices.
“Goldman-Cecil Medicine further
establishes Elsevier as a trusted resource for medical content and world leader
in relevant, robust content,” said Linda Belfus, Senior Vice President of Content,
Elsevier Clinical Solutions. “The material contained in this reference has been
provided by a veritable who’s who of modern medicine to help physicians and
medical students be the best doctors they can be.”
Goldman-Cecil Medicine is currently available for order in print and eBook. The print copy of the book will include the Expert Consult eBook edition, which is compatible with PC, Mac and most mobile devices and eReaders, and allows readers to browse, search, and interact with the content of the book. To purchase the print version please visit www.us.elsevierhealth.com.
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Director, Corporate Relations
+1 212 633 3164